Company profile: Fluidx Medical Technology
1.1 - Company Overview
Company description
- Provider of embolic devices and platforms for targeted vessel occlusion, designed for ease of use and delivery control, including GPX liquid embolic for deep occlusion in oncology and other uses; ULTRA peripheral embolic products with varied occlusion levels for hemorrhage; IMPASS neurovascular embolic for deep, distal penetration and middle meningeal artery embolization; and GPX-Clear with non-artifact radiopacity that dissipates for unobstructed visibility.
Products and services
- GPX Embolic Device: Liquid embolic agent engineered for ease-of-use, versatility, and improved delivery control, enabling deep vessel occlusion for oncology and other applications with highly targeted vessel closure
- IMPASS Embolic Device: Neurovascular embolic agent engineered for deep, distal penetration to achieve highly targeted occlusion, suitable for oncology uses and middle meningeal artery embolization
- ULTRA Embolic Platform: Peripheral embolic product portfolio delivering various levels of occlusion with ease-of-use and control during delivery, applicable to hemorrhage and other peripheral applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Fluidx Medical Technology
AdjuCor
HQ: Germany
Website
- Description: Provider of reBEAT, a minimally invasive, epicardial, biventricular mechanical circulatory support device that assists one or both ventricles of the failing heart without blood contact; responsible for development, production, marketing, and selling of this technology for heart failure patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdjuCor company profile →
X-Ceptor Therapeutics
HQ: United States
Website
- Description: Provider of novel small molecule therapeutics that modulate nuclear receptors, along with a drug discovery platform for the nuclear receptor gene family, developing candidates to treat cardiovascular and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full X-Ceptor Therapeutics company profile →
Celladon
HQ: United States
Website
- Description: Provider of biotechnology focused on developing molecular therapies for the treatment of heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celladon company profile →
Topera Medical
HQ: United States
Website
- Description: Provider of a novel 3D analysis and mapping system to assist electrophysiologists in identifying the electrical source of complex cardiac arrhythmias, comprising the RhythmView Workstation and FIRMap diagnostic catheter.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Topera Medical company profile →
AtriCure
HQ: United States
Website
- Description: Provider of cardiac surgery technologies: systems for surgical ablation of persistent and long-standing persistent atrial fibrillation (Isolator Synergy, EPi-Sense), cryoablation for AF during cardiac surgery (cryoICE), left atrial appendage exclusion devices to reduce stroke risk (AtriClip, AtriClip PRO), and a probe for temporary peripheral nerve ablation to block pain in cardiac and thoracic procedures (cryoICE cryoSPHERE).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AtriCure company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Fluidx Medical Technology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Fluidx Medical Technology
2.2 - Growth funds investing in similar companies to Fluidx Medical Technology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Fluidx Medical Technology
4.2 - Public trading comparable groups for Fluidx Medical Technology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →